MM
FOLD

MQS Management’s Amicus Therapeutics FOLD Stock Holding History

MQS Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,905
Closed -$242K – 527
2023
Q3 		$242K Buy
+19,905
New +$257K 0.15% 304
2023
Q2 		– Sell
-14,350
Closed -$159K – 480
2023
Q1 		$159K Buy
+14,350
New +$177K 0.1% 361

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

MQS Management's FOLD Position: Q4 2023 in Review

MQS Management sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 19,905 shares — an estimated $242K sold.

MQS Management first reported a position in FOLD in Q1 2023 and held it in 2 quarters. The position peaked at $242K in Q3 2023. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

  • MQS Management reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • MQS Management sold 19,905 Amicus Therapeutics shares in Q4 2023, an estimated $242K.
  • MQS Management first reported a position in Amicus Therapeutics in Q1 2023 and held it in 2 quarters.
  • MQS Management's Amicus Therapeutics position peaked at $242K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on MQS Management's 13F filing for Q4 2023, filed 13 Feb 2024.